WO2010034105A8 - Composés inhibiteurs de l'hépatite c - Google Patents

Composés inhibiteurs de l'hépatite c Download PDF

Info

Publication number
WO2010034105A8
WO2010034105A8 PCT/CA2009/001237 CA2009001237W WO2010034105A8 WO 2010034105 A8 WO2010034105 A8 WO 2010034105A8 CA 2009001237 W CA2009001237 W CA 2009001237W WO 2010034105 A8 WO2010034105 A8 WO 2010034105A8
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
inhibitor compounds
analogs
compounds
treatment
Prior art date
Application number
PCT/CA2009/001237
Other languages
English (en)
Other versions
WO2010034105A1 (fr
Inventor
Jeffrey O'meara
Josée BORDELEAU
Vida Gorys
Mélissa LEBLANC
Kirsten Lenhardt
Montse Llinas-Brunet
Mathieu Parisien
Marc-André Poupart
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Priority to JP2011527161A priority Critical patent/JP2012502925A/ja
Priority to CA2737958A priority patent/CA2737958A1/fr
Priority to EP09815517A priority patent/EP2344487A4/fr
Publication of WO2010034105A1 publication Critical patent/WO2010034105A1/fr
Publication of WO2010034105A8 publication Critical patent/WO2010034105A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention porte sur des composés représentés par la formule (I) : dans laquelle B, R3, L0, L1, R2, Rc et R1 sont tels que définis dans la description. Les composés sont utiles comme inhibiteurs de la protéase NS3 du VHC pour le traitement d'une infection virale de type hépatite C. En particulier, la présente invention porte sur de nouveaux analogues peptidiques, sur des compositions pharmaceutiques contenant de tels analogues et sur des utilisations de ces analogues dans le traitement d'une infection à VHC.
PCT/CA2009/001237 2008-09-23 2009-09-14 Composés inhibiteurs de l'hépatite c WO2010034105A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2011527161A JP2012502925A (ja) 2008-09-23 2009-09-14 Ｃ型肝炎阻害化合物
CA2737958A CA2737958A1 (fr) 2008-09-23 2009-09-14 Composes inhibiteurs de l'hepatite c
EP09815517A EP2344487A4 (fr) 2008-09-23 2009-09-14 Composés inhibiteurs de l'hépatite c

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9929208P 2008-09-23 2008-09-23
US61/099,292 2008-09-23
US18663209P 2009-06-12 2009-06-12
US61/186,632 2009-06-12

Publications (2)

Publication Number Publication Date
WO2010034105A1 WO2010034105A1 (fr) 2010-04-01
WO2010034105A8 true WO2010034105A8 (fr) 2011-01-06

Family

ID=42059237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2009/001237 WO2010034105A1 (fr) 2008-09-23 2009-09-14 Composés inhibiteurs de l'hépatite c

Country Status (6)

Country Link
EP (1) EP2344487A4 (fr)
JP (1) JP2012502925A (fr)
AR (1) AR073659A1 (fr)
CA (1) CA2737958A1 (fr)
TW (1) TW201016694A (fr)
WO (1) WO2010034105A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
KR20110075019A (ko) * 2008-10-15 2011-07-05 인터뮨, 인크. 치료용 항바이러스성 펩티드
WO2012092409A2 (fr) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Inhibiteurs macrocycliques de sérine protéase d'hépatite c
EP2658858A4 (fr) 2010-12-30 2014-06-25 Enanta Pharm Inc Inhibiteurs macrocycliques de phénanthridine de sérine protéase d'hépatite c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
PT2909205T (pt) 2012-10-19 2017-02-06 Bristol Myers Squibb Co Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370396A1 (fr) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
CN1791599A (zh) * 2003-05-21 2006-06-21 贝林格尔.英格海姆国际有限公司 丙型肝炎抑制剂化合物
EP1753775B1 (fr) * 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Processus de preparation d'inhibiteurs de protease hcv acyclique
US7705146B2 (en) * 2004-06-28 2010-04-27 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor peptide analogs
AP2874A (en) * 2007-06-29 2014-03-31 Gilead Sciences Inc Antiviral compounds
CA2692145C (fr) * 2007-06-29 2015-03-03 Gilead Sciences, Inc. Composes antiviraux
JP5529036B2 (ja) * 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド フッ素化トリペプチドｈｃｖセリンプロテアーゼ阻害剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
EP2344487A1 (fr) 2011-07-20
EP2344487A4 (fr) 2012-03-21
AR073659A1 (es) 2010-11-24
JP2012502925A (ja) 2012-02-02
CA2737958A1 (fr) 2010-04-01
TW201016694A (en) 2010-05-01
WO2010034105A1 (fr) 2010-04-01

Similar Documents

Publication Publication Date Title
WO2010034105A8 (fr) Composés inhibiteurs de l'hépatite c
MY164469A (en) Hcv ns3 protease inhibitors
WO2008021936A3 (fr) Inhibiteurs du virus de l'hépatite c
WO2008057208A3 (fr) Inhibiteurs de protéase ns3 du vhc
WO2008051514A3 (fr) Inhibiteurs de la protéase ns3 du hcv
WO2008051475A3 (fr) Inhibiteurs de la protéase ns3 du vhc
UA83046C2 (ru) Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
EP1924593B8 (fr) Inhibiteurs de la protease ns3 du vhc
WO2008057995A3 (fr) Inhibiteurs de protéase de vhc
WO2008021927A3 (fr) Inhibiteurs du virus de l'hépatite c
MX2009009174A (es) Inhibidores de serina-proteasas para el tratamiento de infecciones por el virus de hepatitis c.
WO2008051477A3 (fr) Inhibiteurs de la protéase hcv ns3
WO2006119061A3 (fr) Inhibiteurs de la protease ns3 du vhc
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
HK1125576A1 (en) Hepatitis c virus inhibitors
WO2007008657A3 (fr) Inhibiteurs du virus de l'hepatite c
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
IL198741A0 (en) Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
WO2008057871A3 (fr) Inhibiteurs du virus de l'hépatite c
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
WO2008057875A3 (fr) Inhibiteurs du virus de l'hépatite c
WO2004032827A3 (fr) Inhibiteurs du virus de l'hepatite c

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09815517

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase in:

Ref document number: 2011527161

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2737958

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009815517

Country of ref document: EP